Ask about this productRelated genes to: CFTR antibody
- Gene:
- CFTR NIH gene
- Name:
- cystic fibrosis transmembrane conductance regulator
- Previous symbol:
- CF, ABCC7
- Synonyms:
- MRP7, ABC35, TNR-CFTR, dJ760C5.1, CFTR/MRP
- Chromosome:
- 7q31.2
- Locus Type:
- gene with protein product
- Date approved:
- 1986-01-01
- Date modifiied:
- 2019-04-23
Related products to: CFTR antibody
Related articles to: CFTR antibody
- https://bit.ly/4pVfCUq. - Source: PubMed
Publication date: 2026/04/27
Gentzsch MartinaBoyles Susan EMinges John TCholon Deborah MOkuda KenichiRibeiro Carla M P - The gut microbiome is a key modulator of human health throughout life, from infancy to old age. Within this relatively young field, microbiome characteristics are being utilized as useful clinical endpoints and indicators of health. Moreover, microbiome-based interventions have been developed to modulate the gut microbiome to ameliorate a range of disorders, including inflammatory bowel disease, obesity, and diabetes. Conversely, there is a paucity of knowledge on the cystic fibrosis (CF) gut microbiome, despite its obvious importance in gastrointestinal (GI) symptoms in this disorder. In this short review we focus on recent findings in CF gut microbiome research and draw upon advances and knowledge from the wider field of gut microbiome research. We recommend increased efforts to improve our understanding of the CF gut microbiome, with knowledge transfer from the field of gut microbiome research being a pragmatic approach to both guiding and providing novel interventions to manage and improve CF GI pathophysiology and associated comorbidities. - Source: PubMed
Publication date: 2026/05/09
Marsh RyanTricker James MDelhaes LaurenceBomberger Jennifer Mvan der Gast Christopher - To date clinical trials of cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapies have focused on outcomes that can be captured under relatively short follow-up periods. The effectiveness of CFTR modulator therapies on survival has not been fully described. - Source: PubMed
Publication date: 2026/05/08
Kurgansky Katherine ECollaco Joseph MNg Derek KLesko Catherine R - In this report we demonstrate that iodogallic acid (IGA) and iodoferulic acid (IFA) do not acutely affect transepithelial cation transport, however, prolonged basolateral application of IFA induced a delayed decrease in open-circuit current associated with increased transepithelial resistance. IGA and IFA have differential effects on volume-regulated anion currents (VRAC) and on cAMP-induced anion currents. In L929 cells, while IFA did not affect VRAC, IGA had a reversible and slightly voltage-dependent inhibitory effect with apparent IC50 values of approximately 10 μM that decreased with higher membrane voltage depolarization. On the other hand, IGA failed to inhibit cAMP-activated currents in Caco-2 cells, while IFA (100 μM) had a small but statistically significant inhibitory effect that was fully reversible. IGA and IFA exhibit differential effects on anion conductances and may represent candidate pharmacological tools for studying chloride channels, although their selectivity profile requires further characterization. - Source: PubMed
Publication date: 2026/05/08
Mies FrédériqueOlchowik-Grabarek EwaCrutzen RaphaelShlyonsky Vadim - - Source: PubMed
Publication date: 2026/05/10